

CLAIMS:

1. A method of removing LPS from an AAG containing preparation comprising contacting said preparation with a finely divided non-toxic resin.
2. A method as claimed in claim 1 wherein the resin is a non-substituted resin.
3. A method as claimed in any one of the preceding claims wherein the resin is a particulate resin.
4. A method as claimed in any one of the preceding claims wherein the resin is an inorganic resin.
5. A method as claimed in any one of the preceding claims wherein the resin is a hydrophilic resin.
6. A method as claimed in any one of the preceding claims wherein the resin is silane-based.
7. A method as claimed in any one of the preceding claims wherein the resin comprises fumed silica.
8. A method of purifying AAG comprising contacting an AAG-containing preparation with an anion exchange matrix, eluting an AAG-enriched fraction from said matrix and depyrogenating an AAG-enriched fraction by contact with a finely divided non-toxic particulate resin followed by elution of an LPS-depleted AAG fraction.
9. A method as claimed in claim 8 wherein the AAG containing preparation is Cohn Fraction V supernatant.
10. A method as claimed in claim 8 or 9 wherein the AAG containing preparation is contacted with the anion

exchange matrix in the presence of a 30 to 45% ethanolic solution.

11. A method as claimed in any one of claims 8 to 10 wherein the AAG containing material:anion exchange matrix ratio is from 1000:1 to 5:1.

12. A method as claimed in any one of claims 8 to 11 wherein the eluted AAG enriched preparation is neutralized prior to depyrogenation.

13. A method as claimed in any one of the preceding claims wherein the ratio of finely divided non-toxic resin to AAG protein is from 50:1 to 0.2:1 (w/w).

14. A method as claimed in any one of the preceding claims wherein in the depyrogenation step the AAG concentration in solution is from 0.1 to 250 g/L.

15. A method as claimed in any one of the preceding claims wherein the depyrogenated AAG is concentrated.

16. A method as claimed in any one of the preceding claims which additionally comprises a virus inactivation step.

17. A method as claimed in claim 16 wherein the virus inactivation step comprises pasteurization.

18. A method as claimed in claim 16 wherein the virus inactivation step comprises filtration.

19. AAG substantially free of LPS, said AAG having a LPS concentration of less than or equal to 0.1 Eu/mg AAG.

20. AAG as claimed in claim 19 wherein the AAG has a

209220"5262800T

LPS level of less than 0.075 Eu/mg AAG.

21. AAG as claimed in claim 19 or claim 20 wherein the AAG has a LPS level of less than 0.050 Eu/mg AAG.

22. A virus inactivated or a virus depleted Apo-AAG preparation.

23. Apo-AAG for use in therapy.

24. Apo-AAG for use in treatment of drug toxicity.

25. The use of Apo-AAG in the manufacture of a medicament for use in the treatment of drug toxicity.

26. A pharmaceutical composition comprising Apo-AAG together with one or more pharmaceutically acceptable carriers or excipients.

20080520 15:22:00